Synonyms: Avonex® | Rebif®
IFN-β1a (recombinant human) is an approved drug (FDA (1996), EMA (1997))
Compound class:
Peptide
Comment: Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).
|
Classification ![]() |
|
Compound class | Peptide |
Approved drug? | Yes (FDA (1996), EMA (1997)) |
Approved drug? | Yes. FDA (1996) | EMA (1997) |
International Nonproprietary Names ![]() |
|
INN number | INN |
5380 | interferon beta |
Synonyms ![]() |
Avonex® | Rebif® |
Database Links ![]() |
|
DrugBank Ligand | DB00060 |
GtoPdb PubChem SID | 252166551 |
Search PubMed clinical trials | interferon beta |
Search PubMed titles | interferon beta |
Search PubMed titles/abstracts | interferon beta |
Wikipedia | Interferon_beta_1a |